Influenza is tricky due to its mutations. Every time, it emerges anew. Therefore, it is very difficult to come up with an “antidote”, although “difficult” does not mean “impossible”.
Influenza, unlike other acute respiratory viral infections (ARVI), has a short incubation period – from a couple of days to just a few hours.
It is one of the most aggressive and unpredictable diseases that stands out among known infections due to
· Global prevalence;
Influenza is continuously changing. While other infections are rather stable in terms of their structure, there are, e.g., 16 influenza A varieties (the total number of possible combinations theoretically reaches 144, of which 86 have been discovered in the nature).
Despite scientific advances, emergence of new efficacious medications, and treatment methods, this dangerous infection has not been completely eradicated so far. Influenza remains one of the most pressing medical and social issues on the world scale.
The WHO considers vaccination the most significant and efficient influenza management measure. According to the WHO, vaccination reduces morbidity by 90%, and complication-related hospital admissions by 48%. Mass immunization, and influenza vaccination inclusion in the State Program Zdorovye (Health), and the National Immunization Schedule have immediately proved effective. The 1996-2014 study data published in the Epidemiology and Vaccination journal (February 2016) demonstrated that, over the period studied, vaccination coverage in Russia increased from 0.2% (18,672 people, including 52 children) in 1997-1998 season to 25.6% in 2010-2011 season (2,683,146 people, including 1,116,124 children); influenza morbidity rate decreased 154.5-fold.
Mass influenza immunization being implemented in conformance with the WHO guidelines has yielded convincing results: the use of influenza vaccines provided for a morbidity risk decrease in healthy population by 70%—90%. Besides, vaccination of the elderly decreases the number of severe disease cases and complications by 60%, and lethal cases – by 80%.
This influenza management method is a priority in Russia, too. Within the framework of the National Immunization Schedule, immunization covers children aged 6 months and older; secondary school students, grades 1—11; university, and vocational school students; adults of specific professions and jobs (medical, educational, transportation, and utilities workers, etc.); and adults aged 60+. Since 2014, vaccination is additionally indicated in pregnant women, persons subject to military service, and patients with chronic diseases.
In Russia, the latest generation Grippol vaccines are widely used for influenza vaccination. Grippol plus vaccine has a high safety profile being preservative-free. This vaccine has been for many years used to immunize children (including infants aged 6 months and older), pregnant women, and patients with various diseases.
Grippol plus efficacy has been proved by post-marketing epidemiological studies, and many-year experience of the use. In particular, it has been demonstrated that Grippol plus vaccination decreases the ARVI incidence rate in children 1.4-fold, and influenza incidence rate – 4.7-fold (Ilyina TN. Assessment of epidemiological efficacy of influenza vaccine. Modern Pediatrics Issues, 5, v.8, 2009:48-52).Importantly, Grippol plus is the local vaccine that conforms to the WHO requirements for up-to-date adjuvant influenza vaccines. It is manufactured in disposable syringes at a state-of-the-art facility in compliance with the applicable Russian and international GMP standards. Over 8 years of Grippol plus use, more than 100 million people were successfully vaccinated. Due to its high efficacy, quality, and safety profile, Grippol® plus is widely used on the Russian market, has an 8-year positive experience of use within the framework of the National Immunization Schedule in children and pregnant women, and is exported to the CIS and Iran.